In the last trading session, 1.43 million shares of the ARS Pharmaceuticals Inc (NASDAQ:SPRY) were traded, and its beta was 1.00. Most recently the company’s share price was $11.74, and it changed around -$0.18 or -1.51% from the last close, which brings the market valuation of the company to $1.14B. SPRY currently trades at a discount to its 52-week high of $18.51, offering almost -57.67% off that amount. The share price’s 52-week low was $6.33, which indicates that the current value has risen by an impressive 46.08% since then. We note from ARS Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 1.4 million shares, with the 3-month average coming to 1.36 million.
ARS Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended SPRY as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. ARS Pharmaceuticals Inc is expected to report earnings per share of -0.11 for the current quarter.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
Instantly SPRY has showed a red trend with a performance of -1.51% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 13.13 on recent trading dayincreased the stock’s daily price by 10.59%. The company’s shares are currently up 11.28% year-to-date, but still down -4.63% over the last five days. On the other hand, ARS Pharmaceuticals Inc (NASDAQ:SPRY) is 2.71% up in the 30-day period. We can see from the shorts that 14.81 million shares have been sold at a short interest cover period of 10.31 day(s).
The consensus price target as assigned by Wall Street analysts is $26, which translates to bulls needing to increase their stock price by 54.85% from its current value. Analyst projections state that SPRY is forecast to be at a low of $22 and a high of $30.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
The year-over-year growth rate is expected to be 60,031.33%, up from the previous year.
Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 17.68M in revenue for the current quarter. 4 analysts expect ARS Pharmaceuticals Inc to make 16.3M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -1.44%.
SPRY Dividends
ARS Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in March.
ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 23.83% of ARS Pharmaceuticals Inc shares, and 69.14% of them are in the hands of institutional investors. The stock currently has a share float of 90.78%. ARS Pharmaceuticals Inc stock is held by 217.0 institutions, with DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) being the largest institutional investor. By 2024-06-30, it held 11.4409% of the shares, which is about 11.08 million shares worth $94.27 million.
RA CAPITAL MANAGEMENT, L.P., with 11.2168% or 10.86 million shares worth $92.43 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 1.86 shares worth $21.87 million, making up 1.92% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 1.38 shares worth around $16.23 million, which represents about 1.42% of the total shares outstanding.
